BeyondSpring gets FDA Fast Track for plinabulin, sells China unit stake to fund trial
The FDA granted Fast Track status for plinabulin plus docetaxel in post-ICI NSCLC as BeyondSpring agreed to sell its Chinese subsidiary stake to Biolin Investment to fund the trial's China enrollment.
SEC filing